{
  "FullStudy":{
    "Rank":483,
    "Study":{
      "ProtocolSection":{
        "IdentificationModule":{
          "NCTId":"NCT05540262",
          "OrgStudyIdInfo":{
            "OrgStudyId":"GXEDAON1.0"
          },
          "Organization":{
            "OrgFullName":"First Affiliated Hospital of Guangxi Medical University",
            "OrgClass":"OTHER"
          },
          "BriefTitle":"Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis",
          "OfficialTitle":"Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis"
        },
        "StatusModule":{
          "StatusVerifiedDate":"September 2022",
          "OverallStatus":"Recruiting",
          "ExpandedAccessInfo":{
            "HasExpandedAccess":"No"
          },
          "StartDateStruct":{
            "StartDate":"September 15, 2022",
            "StartDateType":"Anticipated"
          },
          "PrimaryCompletionDateStruct":{
            "PrimaryCompletionDate":"December 31, 2024",
            "PrimaryCompletionDateType":"Anticipated"
          },
          "CompletionDateStruct":{
            "CompletionDate":"December 31, 2024",
            "CompletionDateType":"Anticipated"
          },
          "StudyFirstSubmitDate":"September 11, 2022",
          "StudyFirstSubmitQCDate":"September 11, 2022",
          "StudyFirstPostDateStruct":{
            "StudyFirstPostDate":"September 14, 2022",
            "StudyFirstPostDateType":"Actual"
          },
          "LastUpdateSubmitDate":"September 13, 2022",
          "LastUpdatePostDateStruct":{
            "LastUpdatePostDate":"September 15, 2022",
            "LastUpdatePostDateType":"Actual"
          }
        },
        "SponsorCollaboratorsModule":{
          "ResponsibleParty":{
            "ResponsiblePartyType":"Principal Investigator",
            "ResponsiblePartyInvestigatorFullName":"Yi Du",
            "ResponsiblePartyInvestigatorTitle":"Dr.",
            "ResponsiblePartyInvestigatorAffiliation":"First Affiliated Hospital of Guangxi Medical University"
          },
          "LeadSponsor":{
            "LeadSponsorName":"First Affiliated Hospital of Guangxi Medical University",
            "LeadSponsorClass":"OTHER"
          }
        },
        "OversightModule":{
          "IsFDARegulatedDrug":"No",
          "IsFDARegulatedDevice":"No"
        },
        "DescriptionModule":{
          "BriefSummary":"Edaravone showed a good effect on promoting remyelination and protecting axons in NMOSD animals. The investigators hypothesize that edaravone can inhibit axonal damage in patients with aquaporin-4 antibody-positive optic neuritis."
        },
        "ConditionsModule":{
          "ConditionList":{
            "Condition":[
              "Optic Neuritis"
            ]
          }
        },
        "DesignModule":{
          "StudyType":"Interventional",
          "PhaseList":{
            "Phase":[
              "Not Applicable"
            ]
          },
          "DesignInfo":{
            "DesignAllocation":"N/A",
            "DesignInterventionModel":"Single Group Assignment",
            "DesignPrimaryPurpose":"Treatment",
            "DesignMaskingInfo":{
              "DesignMasking":"None (Open Label)"
            }
          },
          "EnrollmentInfo":{
            "EnrollmentCount":"18",
            "EnrollmentType":"Anticipated"
          }
        },
        "ArmsInterventionsModule":{
          "ArmGroupList":{
            "ArmGroup":[
              {
                "ArmGroupLabel":"Edaravone",
                "ArmGroupType":"Experimental",
                "ArmGroupInterventionList":{
                  "ArmGroupInterventionName":[
                    "Drug: Edaravone"
                  ]
                }
              }
            ]
          },
          "InterventionList":{
            "Intervention":[
              {
                "InterventionType":"Drug",
                "InterventionName":"Edaravone",
                "InterventionDescription":"Edaravone injection 30mg three times a day",
                "InterventionArmGroupLabelList":{
                  "InterventionArmGroupLabel":[
                    "Edaravone"
                  ]
                }
              }
            ]
          }
        },
        "OutcomesModule":{
          "PrimaryOutcomeList":{
            "PrimaryOutcome":[
              {
                "PrimaryOutcomeMeasure":"Best-corrected visual acuity",
                "PrimaryOutcomeDescription":"Best-corrected visual acuity will be measured by \"Illiterate E\"chart.",
                "PrimaryOutcomeTimeFrame":"18 months"
              }
            ]
          },
          "SecondaryOutcomeList":{
            "SecondaryOutcome":[
              {
                "SecondaryOutcomeMeasure":"Ganglion cell-inner plexiform layer",
                "SecondaryOutcomeDescription":"Ganglion cell-inner plexiform layer will be measured by optical coherence tomography.",
                "SecondaryOutcomeTimeFrame":"18 months"
              },{
                "SecondaryOutcomeMeasure":"Peripapillary retinal nerve fiber layer",
                "SecondaryOutcomeDescription":"Peripapillary retinal nerve fiber layer will be measured by optical coherence tomography.",
                "SecondaryOutcomeTimeFrame":"18 months"
              }
            ]
          }
        },
        "EligibilityModule":{
          "EligibilityCriteria":"Inclusion Criteria:\n\nChinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis\nPatients with a first episode of optic neuritis in either eye\nFirst symptoms of optic neuritis ≤30 days prior to the first administration of edaravone\n\nExclusion Criteria:\n\nMyopia over 6 diopters\nRefractive media opacity affecting assessment of retinal layers and/or visual acuity",
          "HealthyVolunteers":"No",
          "Gender":"All",
          "MinimumAge":"18 Years",
          "MaximumAge":"70 Years",
          "StdAgeList":{
            "StdAge":[
              "Adult",
              "Older Adult"
            ]
          }
        },
        "ContactsLocationsModule":{
          "LocationList":{
            "Location":[
              {
                "LocationFacility":"Yi Du",
                "LocationStatus":"Recruiting",
                "LocationCity":"Nanning",
                "LocationZip":"530021",
                "LocationCountry":"China",
                "LocationContactList":{
                  "LocationContact":[
                    {
                      "LocationContactName":"Yi Du, MD",
                      "LocationContactRole":"Contact",
                      "LocationContactPhone":"+86 771 5356507",
                      "LocationContactEMail":"duyinapoleon@gmail.com"
                    }
                  ]
                }
              }
            ]
          }
        },
        "IPDSharingStatementModule":{
          "IPDSharing":"Undecided"
        }
      },
      "DerivedSection":{
        "MiscInfoModule":{
          "VersionHolder":"September 19, 2022"
        },
        "ConditionBrowseModule":{
          "ConditionMeshList":{
            "ConditionMesh":[
              {
                "ConditionMeshId":"D000009443",
                "ConditionMeshTerm":"Neuritis"
              },{
                "ConditionMeshId":"D000009902",
                "ConditionMeshTerm":"Optic Neuritis"
              }
            ]
          },
          "ConditionAncestorList":{
            "ConditionAncestor":[
              {
                "ConditionAncestorId":"D000010523",
                "ConditionAncestorTerm":"Peripheral Nervous System Diseases"
              },{
                "ConditionAncestorId":"D000009468",
                "ConditionAncestorTerm":"Neuromuscular Diseases"
              },{
                "ConditionAncestorId":"D000009422",
                "ConditionAncestorTerm":"Nervous System Diseases"
              },{
                "ConditionAncestorId":"D000009901",
                "ConditionAncestorTerm":"Optic Nerve Diseases"
              },{
                "ConditionAncestorId":"D000003389",
                "ConditionAncestorTerm":"Cranial Nerve Diseases"
              },{
                "ConditionAncestorId":"D000005128",
                "ConditionAncestorTerm":"Eye Diseases"
              }
            ]
          },
          "ConditionBrowseLeafList":{
            "ConditionBrowseLeaf":[
              {
                "ConditionBrowseLeafId":"M11539",
                "ConditionBrowseLeafName":"Neuritis",
                "ConditionBrowseLeafAsFound":"Neuritis",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"M11985",
                "ConditionBrowseLeafName":"Optic Neuritis",
                "ConditionBrowseLeafAsFound":"Optic Neuritis",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"M12584",
                "ConditionBrowseLeafName":"Peripheral Nervous System Diseases",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M11563",
                "ConditionBrowseLeafName":"Neuromuscular Diseases",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M11984",
                "ConditionBrowseLeafName":"Optic Nerve Diseases",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M5757",
                "ConditionBrowseLeafName":"Cranial Nerve Diseases",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M7423",
                "ConditionBrowseLeafName":"Eye Diseases",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"T4263",
                "ConditionBrowseLeafName":"Optic Neuritis",
                "ConditionBrowseLeafAsFound":"Optic Neuritis",
                "ConditionBrowseLeafRelevance":"high"
              }
            ]
          },
          "ConditionBrowseBranchList":{
            "ConditionBrowseBranch":[
              {
                "ConditionBrowseBranchAbbrev":"BC10",
                "ConditionBrowseBranchName":"Nervous System Diseases"
              },{
                "ConditionBrowseBranchAbbrev":"All",
                "ConditionBrowseBranchName":"All Conditions"
              },{
                "ConditionBrowseBranchAbbrev":"BC11",
                "ConditionBrowseBranchName":"Eye Diseases"
              },{
                "ConditionBrowseBranchAbbrev":"Rare",
                "ConditionBrowseBranchName":"Rare Diseases"
              }
            ]
          }
        },
        "InterventionBrowseModule":{
          "InterventionMeshList":{
            "InterventionMesh":[
              {
                "InterventionMeshId":"D000077553",
                "InterventionMeshTerm":"Edaravone"
              }
            ]
          },
          "InterventionAncestorList":{
            "InterventionAncestor":[
              {
                "InterventionAncestorId":"D000016166",
                "InterventionAncestorTerm":"Free Radical Scavengers"
              },{
                "InterventionAncestorId":"D000000975",
                "InterventionAncestorTerm":"Antioxidants"
              },{
                "InterventionAncestorId":"D000045504",
                "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action"
              },{
                "InterventionAncestorId":"D000018696",
                "InterventionAncestorTerm":"Neuroprotective Agents"
              },{
                "InterventionAncestorId":"D000020011",
                "InterventionAncestorTerm":"Protective Agents"
              },{
                "InterventionAncestorId":"D000045505",
                "InterventionAncestorTerm":"Physiological Effects of Drugs"
              }
            ]
          },
          "InterventionBrowseLeafList":{
            "InterventionBrowseLeaf":[
              {
                "InterventionBrowseLeafId":"M3377",
                "InterventionBrowseLeafName":"Antibodies",
                "InterventionBrowseLeafRelevance":"low"
              },{
                "InterventionBrowseLeafId":"M1831",
                "InterventionBrowseLeafName":"Edaravone",
                "InterventionBrowseLeafAsFound":"FOLFIRINOX",
                "InterventionBrowseLeafRelevance":"high"
              },{
                "InterventionBrowseLeafId":"M9336",
                "InterventionBrowseLeafName":"Immunoglobulins",
                "InterventionBrowseLeafRelevance":"low"
              },{
                "InterventionBrowseLeafId":"M3444",
                "InterventionBrowseLeafName":"Antioxidants",
                "InterventionBrowseLeafRelevance":"low"
              },{
                "InterventionBrowseLeafId":"M19926",
                "InterventionBrowseLeafName":"Neuroprotective Agents",
                "InterventionBrowseLeafRelevance":"low"
              },{
                "InterventionBrowseLeafId":"M21022",
                "InterventionBrowseLeafName":"Protective Agents",
                "InterventionBrowseLeafRelevance":"low"
              }
            ]
          },
          "InterventionBrowseBranchList":{
            "InterventionBrowseBranch":[
              {
                "InterventionBrowseBranchAbbrev":"All",
                "InterventionBrowseBranchName":"All Drugs and Chemicals"
              },{
                "InterventionBrowseBranchAbbrev":"NeuroAg",
                "InterventionBrowseBranchName":"Neuroprotective Agents"
              }
            ]
          }
        }
      }
    }
  }
}

